EP0190857B1 - Quinolone inotropic agents - Google Patents
Quinolone inotropic agents Download PDFInfo
- Publication number
- EP0190857B1 EP0190857B1 EP86300524A EP86300524A EP0190857B1 EP 0190857 B1 EP0190857 B1 EP 0190857B1 EP 86300524 A EP86300524 A EP 86300524A EP 86300524 A EP86300524 A EP 86300524A EP 0190857 B1 EP0190857 B1 EP 0190857B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compound
- formula
- pharmaceutically acceptable
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *C(C1CC2)=CC=CC1N(*)C2=O Chemical compound *C(C1CC2)=CC=CC1N(*)C2=O 0.000 description 9
- BUEVWAGHVDKROX-UHFFFAOYSA-N BN(c(cc1)c(C=C2)cc1C(C=C1)=CCC1(C)C(O)=O)C2=O Chemical compound BN(c(cc1)c(C=C2)cc1C(C=C1)=CCC1(C)C(O)=O)C2=O BUEVWAGHVDKROX-UHFFFAOYSA-N 0.000 description 1
- BGKLFAQCHHCZRZ-UHFFFAOYSA-N Cc1cc(I)ccc1N Chemical compound Cc1cc(I)ccc1N BGKLFAQCHHCZRZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to substituted quinolone cardiac stimulants which in general selectively increase the force of myocardial contraction without producing significant increases in the heart rate.
- the compounds are useful in the curative or prophylactic treatment of cardiac conditions, in particular in the treatment of heart failure.
- EP-A-148623 discloses certain quinolone compounds as inotropic agents.
- R 2 is H or CH 3
- R' is -S(O)m(C 1 -C 4 alkyl) where m is 0, 1 or 2, -S0 2 NH 2 , ⁇ SO 2 NH(C 1 ⁇ C 4 alkyl), -OH, -COOH, ⁇ COO(C 1 ⁇ C 4 alkyl), -CONH 2 , ⁇ CON(C 1 ⁇ C 4 alkyl) 2 , imidazol-1-yl, -OCH 2 (4-pyridyl), ⁇ OCH 2 CH 2 N(C 1 or C 2 alkyl) 2 , ⁇ CON(C 1 ⁇ C 4 alkyl)CH 2 CH 2 N(C 1 or C 2 alkyl) 2 , or ⁇ OCONH(C 1 ⁇ C 4 alkyl), R' being attached to the 2 1 - or 4 1 -position of the benzene ring
- keto-form is considered the more stable tautomer
- the end products herein will be named and illustrated as quinolones although those skilled in the art will realise that both tautomers may be present or that any particular compound so named may exist predominantly as the hydroxy tautomer and the following disclosure is to be interpreted to incorporate all tautomeric forms.
- the group R 1 is preferably in the ortho or para position in the benzene ring, and is most preferably ⁇ ara.
- the most preferred individual compounds of the formula (I) have the formula:- where R 1 is as defined for formula (I) and is preferably ⁇ SOCH 3 , ⁇ OH or ⁇ CONH 2 .
- the most preferred individual compounds have the formula (IB) where R 1 is ⁇ CONH 2 or ⁇ SOCH 3 .
- the pharmaceutically acceptable salts of the compounds of the formulae (I) are either acid addition salts formed from acids which form non-toxic acid addition salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, methanesulphonate and p-toluenesulphonate salts, or are alkali metal or alkaline earth metal salts, particularly the sodium and potassium salts.
- R' is, for example, carboxy and R 6 is H then salt formation is of course possible at two sites in the molecule, e.g.:-
- the cardiac stimulant activity of the compounds of the formula (I) is shown by their effectiveness in one or more of the following tests: (a) increasing the force of contraction in the "Starling" dog heart-lung preparation measured via a left ventricular catheter; (b) increasing myocardial contractility (left ventricular dp/dt max.) in the anaesthetised dog measured via a left ventricular catheter; (c) increasing myocardial contractility in the conscious dog with an implanted left ventricular transducer (dp/dt max.) or an exteriorised carotid artery loop (systolic time intervals).
- test (a) the positive inotropic effect of the test compound following bolus administration is measured in the "Starling" dog heart-lung preparation. The selectivity for increase in force versus frequency of contraction of the test compound is obtained.
- test (b) the positive inotropic action of the test compound following intravenous administration is measured in the anaesthetised dog.
- the magnitude and duration of this action, and the selectivity for increase in force versus frequency of contraction of the test compound are obtained, as are the peripheral effects, e.g. the effect on blood pressure.
- test (c) the positive inotropic action of the test compound following intravenous or oral administration to a conscious dog with an implanted left ventricular transducer (dp/dt max.) or an exteriorised carotid artery loop (systolic time intervals) is measured.
- the magnitude of the inotropic action, the selectivity for increase in force versus frequency of contraction, and the duration of action of the inotropic effect of the test compound are all obtained.
- the compounds of the formula (I) can be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents.
- They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously.
- parenteral administration they are best used in the form of a sterile aqueous solution which may contain other solutes, for example, enough salts or glucose to make the solution isotonic.
- oral dosages of the compounds of the invention will be in the range from 10 mg to 1 g daily, taken in 2 to 4 divided doses per day, for an average adult patient (70 kg). Dosages for intravenous administration would be expected to be within the range 0.5 to 100 mg per single dose as required, for example in the treatment of acute heart failure. Thus for a typical adult patient, individual tablets or capsules might contain 2.5 to 250 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Variations may occur depending on the weight and condition of the subject being treated as will be known to medical practitioners.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I) as defined above or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
- the invention also provides a method of stimulating the heart of an animal, including a human being, which comprises administering to the animal a compound of formula (I) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined above, in an amount sufficient to stimulate the heart of the animal.
- the invention yet further provides a compound of the formula (I) or pharmaceutically acceptable salt thereof, for use in medicine, in particular for use in stimulating the heart of a human being suffering from congestive heart failure.
- the compounds of the formula (1) can be prepared by a number of routes, including the following:-
- R 1 , R 2 , X, n and the dotted line are as defined for formula (I).
- the demethylation is preferably carried out by heating the methoxyquinoline (II) either in aqueous mineral acid, typically in aqueous HCI or HBr and preferably in 48% HBr or 5 or 6M HCI, or in ethanol containing a catalytic quantity (generally 5-15% by volume) of 48% aqueous HBr, at up to reflux temperature for 0.5-8 hours.
- the product can then be isolated and purified by conventional procedures.
- R' is an alkoxycarbonyl group (e.g. -COOCH 3 )
- the demethylation may convert this to -COOH, in which case the carboxyl group can be re-esterified conventionally using, e.g., methanol in sulphuric acid.
- novel starting materials of the formula (II) can be prepared by conventional procedures. These compounds form a part of the present invention.
- the reactants are typically heated at up to the reflux temperature in a suitable organic solvent such as tetrahydrofuran for, typically, 1-48 hours.
- a suitable organic solvent such as tetrahydrofuran for, typically, 1-48 hours.
- the intermediates can then be isolated and if necessary purified by conventional techniques.
- the aryl or heteroaryl zinc chlorides can be conventionally obtained by the reaction of the corresponding bromo compound with n- or t-butyllithium and then with anhydrous zinc chloride. Tetrahydrofuran is a suitable solvent for these reactions, which should be carried out at low temperature.
- Compounds in which there is a hydroxy substituent on the phenyl ring can be prepared by the demethylation of the corresponding C l -C 4 alkoxy compounds using conventional demethylation reagents such as aqueous mineral acid (preferably 48% aqueous HBr), boron tribromide or pyridinium hydrobromide. It is preferable to use aqueous mineral acid at up to reflux temperature.
- Hal is Br or I.
- the reaction involves the displacement of the leaving group “Hal” by the aryl zinc chloride with tetrakis (triphenylphosphine)palladium (O) catalysis.
- the reaction is typically carried out by heating the reactants at up to reflux temperature in a suitable organic solvent, e.g. THF.
- Aryl magnesium chlorides can also be used in place of zinc chlorides using other suitable transition metal catalysts (e.g. nickel based).
- the starting materials are either known compounds or are obtainable conventionally.
- the aryl zinc chlorides are most conveniently obtained in situ by reacting the appropriate halo benzene derivative at from -70° to 0°C in THF with n-butyl or t-butyl lithium to obtain the lithio-derivative, followed by reaction of the lithio derivative with a solution of anhydrous zinc chloride in THF.
- the aryl zinc chlorides can also be prepared from the corresponding Grignard reagents by reaction with a solution of zinc chloride in THF.
- the desired end product can then be obtained by allowing the reaction mixture to warm to room temperature, followed by adding the appropriate halo-quinolone and the tetrakis (triphenylphosphine) palladium(O) in THF and then heating under reflux until the reaction is complete (e.g. in 1 to 48 hours).
- the product can then be recovered and purified conventionally.
- halo-quinolone starting materials of this route can also be prepared by conventional procedures. Typical routes to these materials, many of which are illustrated in detail in the following Preparations, are as follows:-
- R 7 is C 1 -C 4 alkyl, ⁇ CH 2 CH 2 N(C 1 or C 2 alkyl) 2 or HetCH 2 -.
- reaction involves alkylation of the phenolic hydroxyl group in the presence of triphenyl phosphine and diethylazodicarboxylate.
- the reaction is typically carried out in an inert organic solvent (e.g. THF) at up to the reflux temperature.
- THF inert organic solvent
- reaction involves conversion of the phenolic hydroxyl group to an N-alkylcarbamoyloxy group using a C 1 -C 4 alkyl isocyanate.
- the reaction is typically carried out in a suitable organic solvent such as THF at up to reflux temperature.
- THF a suitable organic solvent
- the products can then be purified conventionally.
- the acid chlorides are typically obtained by alkaline hydrolysis of the corresponding C l -C 4 alkyl esters followed by conversion of the resulting carboxylic acid salt (e.g. the sodium salt) to the acid chloride by treatment with thionyl chloride. Reaction of the crude acid chloride with ammonia or the appropriate amine then yields the desired end products which can be isolated and purified conventionally.
- carboxylic acid salt e.g. the sodium salt
- oxidising agents are peracid oxidising agents such as m-chloroperbenzoic acid.
- Compounds having a single bond in the 3,4-position can be obtained by the hydrogenation of the corresponding compounds having a double bond in the 3,4-position according to conventional techniques, e.g. using H 2 over Pd/C.
- the reaction is carried out in an organic solvent such as ethanol at 25-100°C and under 101-33667 kPa hydrogen pressure over palladised charcoal until the reaction is complete.
- R 3 is a C l -C 4 alkyl group
- R 3 is H
- quinolone starting material sodium hydride or other strong base
- reaction with a C 1 ⁇ C 4 alkyl halide or di(C l -C 4 alkyl)sulphate in a conventional manner.
- Salts of the compounds of the formula (I) are preparable by entirely conventional methods, e.g. by reacting a solution of the compound (I) in an organic solvent with a solution of an appropriate acid in an organic solvent to form an acid addition salt, or by reacting the compound (I) with an appropriate base, e.g. an alkali metal or alkaline earth metal hydroxide, preferably aqueous sodium hydroxide, to form a pharmaceutically acceptable metal salt.
- an appropriate base e.g. an alkali metal or alkaline earth metal hydroxide, preferably aqueous sodium hydroxide
- the invention includes the separated enantiomers and diastereoisomers or mixtures thereof.
- the separated forms can be obtained by conventional means.
- Example 1 The following compounds were prepared similarly to Example 1 starting from the appropriately substituted 2-methoxyquinoline and either 5M aqueous HCI (Examples 2-9), 6M aqueous HCI (Example 12) or 48% aqueous HBr (Examples 10 and 11).
- t-Butyllithium (30 cm 3 of a 2.0 M solution in n-pentane) was added dropwise at -70° to a stirred solution of 6-bromo-2-methoxyquinoline (7.14 g) in tetrahydrofuran (THF) (50 cm 3 ) under nitrogen. After 10 minutes a solution of anhydrous zinc chloride (4.09 g) in THF (30 cm 3 ) was added and the solution was allowed to warm to room temperature. A mixture of methyl 4-iodobenzoate (7.8 g) and tetrakis (triphenylphosphine) palladium (0) (0.32 g) was added and the mixture was heated under reflux for 1 hour.
- n-Butyllithium (33.3 cm 3 of a 1.5 M solution of n-hexane) was added dropwise at -70° to a stirred solution of 4-bromoanisole (6.26 cm 3 ) in THF (70 cm 3 ) under nitrogen. After ten minutes, a solution of anhydrous zinc chloride (6.814 g) in THF (50 cm 3 ) was added and the mixture was allowed to warm to room temperature over 0.5 hour. A mixture of 6-bromo-2-methoxy-8-methylquinoline (12.8 g) and tetrakis (triphenylphosphine) palladium (0) (0.5 g) was added and the mixture heated under reflux for 2 hours.
- 6-Bromo-2-(1H)-quinoiine is a known compound.
- 6-Bromo-2-methoxy-8-methylquinoline m.p. 89-91°
- 6-bromo-2-chloro-8-methylquinoline and sodium methoxide was prepared similarly to the previous Preparation using 6-bromo-2-chloro-8-methylquinoline and sodium methoxide as the starting materials.
- 6-Bromo-2-chloroquinoline is a known compound.
- Trans-3-ethoxypropenoyl chloride (0.74 g) was added at 0° to a stirred solution of 4-bromo-2-methylaniline (0.93 g) in pyridine (10 cm 3 ). After 0.5 hours water (40 cm 3 ) was added, the solid material was filtered off, washed with water (30 cm 3 ) and dried. The product was recrystallised from ethyl acetate to afford trans-N-(4-bromo-2-methylphenyl)-3-ethoxypropenamide, m.p. 163-164°, (1.3 g).
- Trans-N-(4-iodophenyl)-3-ethoxypropenamide m.p. 181-182°
- 6-lodo-2-(lH)-quinolone m.p. 260-263°
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Abstract
Description
- This invention relates to substituted quinolone cardiac stimulants which in general selectively increase the force of myocardial contraction without producing significant increases in the heart rate. The compounds are useful in the curative or prophylactic treatment of cardiac conditions, in particular in the treatment of heart failure.
- EP-A-148623 discloses certain quinolone compounds as inotropic agents.
- According to the present invention there are provided compounds having the general formula:-
-
- However, as the keto-form is considered the more stable tautomer, the end products herein will be named and illustrated as quinolones although those skilled in the art will realise that both tautomers may be present or that any particular compound so named may exist predominantly as the hydroxy tautomer and the following disclosure is to be interpreted to incorporate all tautomeric forms.
- The group R1 is preferably in the ortho or para position in the benzene ring, and is most preferably αara.
- Preferably, R1 is ―S(O)mCH3 where m is 0, 1 or 2, -S02NH2, -S02NHCH3, -S02N(CH3)2, -NH2, -OCH3, -OH, -COOH, ―COOCH3, ―CONH2, -CON(CH3)2, imidazol-1-yl, -OCH2(4-pyridyl), ―OCH2CH2N(CH3)2, ―CON(CH3)CH2CH2N(CH3)2 or ―OCONH(n-propyl) where R2 = CH3.
-
- The most preferred individual compounds have the formula (IB) where R1 is ―CONH2 or ―SOCH3.
- The pharmaceutically acceptable salts of the compounds of the formulae (I) are either acid addition salts formed from acids which form non-toxic acid addition salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, methanesulphonate and p-toluenesulphonate salts, or are alkali metal or alkaline earth metal salts, particularly the sodium and potassium salts. When R' is, for example, carboxy and R6 is H then salt formation is of course possible at two sites in the molecule, e.g.:-
- The cardiac stimulant activity of the compounds of the formula (I) is shown by their effectiveness in one or more of the following tests: (a) increasing the force of contraction in the "Starling" dog heart-lung preparation measured via a left ventricular catheter; (b) increasing myocardial contractility (left ventricular dp/dt max.) in the anaesthetised dog measured via a left ventricular catheter; (c) increasing myocardial contractility in the conscious dog with an implanted left ventricular transducer (dp/dt max.) or an exteriorised carotid artery loop (systolic time intervals).
- In test (a), the positive inotropic effect of the test compound following bolus administration is measured in the "Starling" dog heart-lung preparation. The selectivity for increase in force versus frequency of contraction of the test compound is obtained.
- In test (b), the positive inotropic action of the test compound following intravenous administration is measured in the anaesthetised dog. The magnitude and duration of this action, and the selectivity for increase in force versus frequency of contraction of the test compound are obtained, as are the peripheral effects, e.g. the effect on blood pressure.
- In test (c) the positive inotropic action of the test compound following intravenous or oral administration to a conscious dog with an implanted left ventricular transducer (dp/dt max.) or an exteriorised carotid artery loop (systolic time intervals) is measured. The magnitude of the inotropic action, the selectivity for increase in force versus frequency of contraction, and the duration of action of the inotropic effect of the test compound are all obtained.
- The compounds of the formula (I) can be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other solutes, for example, enough salts or glucose to make the solution isotonic.
- For administration to man in the curative or prophylactic treatment of cardiac conditions such as congestive heart failure, it is expected that oral dosages of the compounds of the invention will be in the range from 10 mg to 1 g daily, taken in 2 to 4 divided doses per day, for an average adult patient (70 kg). Dosages for intravenous administration would be expected to be within the range 0.5 to 100 mg per single dose as required, for example in the treatment of acute heart failure. Thus for a typical adult patient, individual tablets or capsules might contain 2.5 to 250 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Variations may occur depending on the weight and condition of the subject being treated as will be known to medical practitioners.
- Thus the present invention provides a pharmaceutical composition comprising a compound of the formula (I) as defined above or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
- The invention also provides a method of stimulating the heart of an animal, including a human being, which comprises administering to the animal a compound of formula (I) or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined above, in an amount sufficient to stimulate the heart of the animal.
- The invention yet further provides a compound of the formula (I) or pharmaceutically acceptable salt thereof, for use in medicine, in particular for use in stimulating the heart of a human being suffering from congestive heart failure.
- The compounds of the formula (1) can be prepared by a number of routes, including the following:-
-
- R1, R2, X, n and the dotted line are as defined for formula (I). The demethylation is preferably carried out by heating the methoxyquinoline (II) either in aqueous mineral acid, typically in aqueous HCI or HBr and preferably in 48% HBr or 5 or 6M HCI, or in ethanol containing a catalytic quantity (generally 5-15% by volume) of 48% aqueous HBr, at up to reflux temperature for 0.5-8 hours. The product can then be isolated and purified by conventional procedures.
- In cases where R' is an alkoxycarbonyl group (e.g. -COOCH3), the demethylation may convert this to -COOH, in which case the carboxyl group can be re-esterified conventionally using, e.g., methanol in sulphuric acid.
-
- The novel starting materials of the formula (II) can be prepared by conventional procedures. These compounds form a part of the present invention.
-
- In both cases, the reactants are typically heated at up to the reflux temperature in a suitable organic solvent such as tetrahydrofuran for, typically, 1-48 hours. The intermediates can then be isolated and if necessary purified by conventional techniques. For further experimental details see the relevant Preparations. The aryl or heteroaryl zinc chlorides can be conventionally obtained by the reaction of the corresponding bromo compound with n- or t-butyllithium and then with anhydrous zinc chloride. Tetrahydrofuran is a suitable solvent for these reactions, which should be carried out at low temperature.
-
- Compounds in which there is a hydroxy substituent on the phenyl ring can be prepared by the demethylation of the corresponding Cl-C4 alkoxy compounds using conventional demethylation reagents such as aqueous mineral acid (preferably 48% aqueous HBr), boron tribromide or pyridinium hydrobromide. It is preferable to use aqueous mineral acid at up to reflux temperature.
-
-
- "Hal" is Br or I. Thus it will be seen that the reaction involves the displacement of the leaving group "Hal" by the aryl zinc chloride with tetrakis (triphenylphosphine)palladium (O) catalysis. The reaction is typically carried out by heating the reactants at up to reflux temperature in a suitable organic solvent, e.g. THF.
-
- Aryl magnesium chlorides can also be used in place of zinc chlorides using other suitable transition metal catalysts (e.g. nickel based).
- The starting materials are either known compounds or are obtainable conventionally.
- The aryl zinc chlorides are most conveniently obtained in situ by reacting the appropriate halo benzene derivative at from -70° to 0°C in THF with n-butyl or t-butyl lithium to obtain the lithio-derivative, followed by reaction of the lithio derivative with a solution of anhydrous zinc chloride in THF. The aryl zinc chlorides can also be prepared from the corresponding Grignard reagents by reaction with a solution of zinc chloride in THF. The desired end product can then be obtained by allowing the reaction mixture to warm to room temperature, followed by adding the appropriate halo-quinolone and the tetrakis (triphenylphosphine) palladium(O) in THF and then heating under reflux until the reaction is complete (e.g. in 1 to 48 hours). The product can then be recovered and purified conventionally.
-
-
- Thus the reaction involves alkylation of the phenolic hydroxyl group in the presence of triphenyl phosphine and diethylazodicarboxylate. The reaction is typically carried out in an inert organic solvent (e.g. THF) at up to the reflux temperature. The product can then be purified conventionally.
-
-
- R4 is a C1―C4 alkyl group.
- Thus the reaction involves conversion of the phenolic hydroxyl group to an N-alkylcarbamoyloxy group using a C1-C4 alkyl isocyanate. The reaction is typically carried out in a suitable organic solvent such as THF at up to reflux temperature. The products can then be purified conventionally.
-
-
- The acid chlorides are typically obtained by alkaline hydrolysis of the corresponding Cl-C4 alkyl esters followed by conversion of the resulting carboxylic acid salt (e.g. the sodium salt) to the acid chloride by treatment with thionyl chloride. Reaction of the crude acid chloride with ammonia or the appropriate amine then yields the desired end products which can be isolated and purified conventionally.
-
- Compounds in which m is 1 or 2 can be prepared by the oxidation of the corresponding compounds in which m is zero using the appropriate quantity of oxidizing agent. The preferred oxidising agents are peracid oxidising agents such as m-chloroperbenzoic acid.
- Compounds having a single bond in the 3,4-position can be obtained by the hydrogenation of the corresponding compounds having a double bond in the 3,4-position according to conventional techniques, e.g. using H2 over Pd/C. Typically the reaction is carried out in an organic solvent such as ethanol at 25-100°C and under 101-33667 kPa hydrogen pressure over palladised charcoal until the reaction is complete.
- Compounds in which R3 is a Cl-C4 alkyl group can be prepared by the N-alkylation of the corresponding compounds in which R3 is H, e.g. by reacting the quinolone starting material with sodium hydride or other strong base to form the anion, followed by reaction with a C1―C4 alkyl halide or di(Cl-C4 alkyl)sulphate in a conventional manner.
- Salts of the compounds of the formula (I) are preparable by entirely conventional methods, e.g. by reacting a solution of the compound (I) in an organic solvent with a solution of an appropriate acid in an organic solvent to form an acid addition salt, or by reacting the compound (I) with an appropriate base, e.g. an alkali metal or alkaline earth metal hydroxide, preferably aqueous sodium hydroxide, to form a pharmaceutically acceptable metal salt.
- Where the compounds of the invention contain one or more asymmetric centres, then the invention includes the separated enantiomers and diastereoisomers or mixtures thereof. The separated forms can be obtained by conventional means.
- The following Examples illustrate the preparation of the compounds (I). (All temperatures are in °C):-
-
-
-
-
- 8-Methyl-6-[4-methoxycarbonylphenyl]-2-(1H)-quinolone.0.5 H20, m.p. 293°, was prepared similarly to Example 13(A) using 2-methoxy-8-methyl-6-(4-methoxycarbonylphenyl)quinoline and 5M HCI.
-
-
-
- Preparation of 6-[4-methoxyphenyl]-2-(1H)-quinolone
-
- A solution of t-butyl lithium (9.0 cm3 of a 2.0 M solution in n-pentane) was added at -70° to a stirred solution of 4-bromoanisole (1.13 cm3) in tetrahydrofuran (THF) (20 cm3) under nitrogen. After 10 minutes a solution of anhydrous zinc chloride (1.23 g) in THF (10 cm3) was added and the mixture was allowed to warm to room temperature over 0.5 hour. A mixture of 6-iodo-2-(lH)-quinolone (0.813 g) and tetrakis (triphenylphosphine) palladium (0) (0.03 g) was added and the mixture was heated under reflux for 2 hours. Volatile material was then removed in vacuo and the residue was partitioned between chloroform:methanol, 9:1 (100 cm3), and a solution of ethylenediaminetetraacetic acid disodium salt (7 g) in water (100 cm3). The aqueous phase was further extracted with chloroform:methanol, 9:1 (3 x 100 cm3), and the combined and dried (MgS04) organic extracts were evaporated to give an oily solid which was triturated with ethyl acetate. Recrystallisation of the residue from ethyl acetate-methanol-chloroform afforded the title compound, m.p. 262―264° (0.359 g).
-
-
- A solution of diethylazodicarboxylate (0.189 cm3) in THF (5 cm3) was added at room temperature to a stirred suspension of 8-methyl-6-[4-hydroxyphenyl]-2-(1H)-quinolone (0.25 g), 4-hydroxymethylpyridine (0.109 g) and triphenylphosphine (0.315 g) in THF (10 cm3) under nitrogen. The mixture was heated under reflux for 18 hours, silica (10 g) (Merck "MK 60.9385" [Trade Mark]) was added and volatile material was removed in vacuo. The residue was placed on top of a silica column (Merck "MK 60.9385" [Trade Mark]) and eluted with ethyl acetate:methanol, 9:1. Combination and evaporation of the appropriate fractions in vacuo gave a solid (0.24 g) which was recrystallised from ethyl acetate-methanol to afford the title compound, m.p. 270.5-273.5°, (0.08 g).
- 8-Methyl-6-[4-(2-dimethylaminoethoxy)phenyl]-2-(1H)-quinolone, m.p. 216° (decomp.), was prepared similarly to the previous Example using 8-methyl-6-[4-hydroxyphenyl]-2-(lH)-quinolone, diethylazodicarboxylate, triphenylphosphine and 2-dimethylaminoethanol as the starting materials.
-
- A solution of 8-methyl-6-[4-hydroxyphenyl]-2-(1 H)-quinolone (0.30 g) and n-propylisocyanate (0.5 cm3) was heated under reflux in THF (10 cm3) under nitrogen for 50 hours. Methanol (10 cm3) was then added to disolve solid material, followed by silica (Merck "MK 60.9385" [Trade Mark]) (10 g), and the volatile material was removed in vacuo. The residue was placed on top of a silica column (Merck "MK 60.9385") and eluted with chloroform:methanol, 19:1. Combination and evaporation of appropriate fractions in vacuo gave a solid which was recrystallised from propan-2-ol to afford the title compound, m.p. 224^228°, (0.28 g).
-
-
- A suspension of 6-[4-carboxyphenyl]-2-(1H)-quinolone disodium salt dihydrate (0.5 g) (see Example 13B) in thionyl chloride (10 cm3) was heated under reflux for 10 minutes. The cooled solution was evaporated in vacuo to afford a yellow solid which was treated without purification with aqueous ammonia solution (5 cm3, S.G. 0.88) with stirring. The solid material was filtered off and warmed with chloroform:methanol, 4:1, to remove soluble impurities and the remaining solid was filtered to afford the title compound, m.p. >320°, (0.3 g).
- The following compounds were prepared similarly to the previous Example using 6-[4-carboxyphenyl]-2-(1H)-quinolone disodium salt dihydrate (Examples 21 and 22 or 8-methyl-6-[4-carboxyphenyl]-2-(1H)-quinolone disodium salt 1.75 hydrate (Example 23), and ammonia or the appropriately substituted amine as the starting materials:-
-
- The following Preparations illustrate the synthesis of certain starting materials. All temperatures are in °C:
-
- t-Butyllithium (30 cm3 of a 2.0 M solution in n-pentane) was added dropwise at -70° to a stirred solution of 6-bromo-2-methoxyquinoline (7.14 g) in tetrahydrofuran (THF) (50 cm3) under nitrogen. After 10 minutes a solution of anhydrous zinc chloride (4.09 g) in THF (30 cm3) was added and the solution was allowed to warm to room temperature. A mixture of methyl 4-iodobenzoate (7.8 g) and tetrakis (triphenylphosphine) palladium (0) (0.32 g) was added and the mixture was heated under reflux for 1 hour. Volatile material was removed in vacuo and the residue was partitioned between chloroform (150 cm3) and a solution of ethylenediaminetetraacetic acid disodium salt (22.4 g) in water (400 cm3). The aqueous phase was further extracted with chloroform (2 x 100 cm3), and the combined and dried (MgSO4) organic extracts were evaporated to give a solid which was recrystallised from acetone to afford the title compound, m.p. 158-161°C, (6.81 g).
-
-
- n-Butyllithium (33.3 cm3 of a 1.5 M solution of n-hexane) was added dropwise at -70° to a stirred solution of 4-bromoanisole (6.26 cm3) in THF (70 cm3) under nitrogen. After ten minutes, a solution of anhydrous zinc chloride (6.814 g) in THF (50 cm3) was added and the mixture was allowed to warm to room temperature over 0.5 hour. A mixture of 6-bromo-2-methoxy-8-methylquinoline (12.8 g) and tetrakis (triphenylphosphine) palladium (0) (0.5 g) was added and the mixture heated under reflux for 2 hours. Volatile material was removed in vacuo and the residue was partitioned between chloroform (150 cm3) and a solution of ethylenediaminetetraacetic acid (40 g) in water (250 cm3). The organic layer was dried (MgS04) and evaporated to afford an oil which was chromatographed on silica (Merck "MK 60.9385" [Trade Mark]) eluting with hexane:ethyl acetate, 19:1. Combination and evaporation of the appropriate fractions afforded the title compound (5.49 g). A small portion of this was recrystallised from methanol and had m.p. of 104^106° and the following analysis:
-
-
- A solution of m-chloroperbenzoic acid (0.56 g) in dichloromethane (5 cm3) was added dropwise at -70° to a stirred solution of 2-methoxy-6-[4-methylthiophenyl]quinoline (0.7 g) in dichloromethane (10 cm3). The mixture was warmed to room temperature over 1 hour, taken into dichloromethane (25 cm3) and washed with sodium carbonate solution (10 cm3). The organic phase was dried (MgS04) and evaporated and the residue was chromatographed on silica (Merck "MK 60.9385" [Trade Mark]) eluting with chloroform: methanol, 19:1. The appropriate fractions were combined and evaporated to give a solid which was recrystallised from acetone-hexane to afford the title compound, m.p. 163.5-165.5°, (0.55 g).
-
-
- A solution of m-chloroperbenzoic acid (1.12 g) in dichloromethane (5 cm3) was added dropwise at -700 to a stirred solution of 2-methoxy-6-[4-methylthiophenyl]quinoline (0.7 g) in dichloromethane (10 cm3). The mixture was allowed to warm to room temperature over one hour and the solution was washed with saturated sodium carbonate solution (10 cm3). The organic phase was dried (MgS04) and evaporated in vacuo to give a solid which was recrystallised from ethyl acetate to afford the title compound, m.p. 182-184° (0.674 g).
-
- A mixture of 6-bromo-2-[1H]-quinolone (2.90 g) and trimethyloxoniumtetrafluoroborate (2.10 g) was stirred in dichloromethane (50 cm3) for 48 hours under nitrogen. Aqueous 10% sodium hydroxide (20 cm3) was added and the aqueous phase was extracted with dichloromethane (2 x 40 cm3). The dried (MgS04) extracts were evaporated and the residue was crystallised from petroleum ether (b.p. 60-80°) to yield the title compound, m.p. 90-94°, (2.16 g).
- 6-Bromo-2-(1H)-quinoiine is a known compound.
-
- A solution of 2-chloro-6-bromoquinoline (4.0 g) in methanol (20 cm3) was heated under reflux with sodium methoxide [made from sodium (0.5 g) and methanol (20 cm3)] for 16 hours. The solvent was removed in vacuo and the residue was partitioned, between water (20 cm3) and chloroform (100 cm3). The aqueous phase was extracted with chloroform (2 x 30 cm3) and the dried (MgS04) organic extracts were evaporated to give a solid which was recrystallised from petroleum ether (b.p. 60―80°) to yield the title compound, m.p. 93-96°, (3.0 g).
- 6-Bromo-2-methoxy-8-methylquinoline, m.p. 89-91°, was prepared similarly to the previous Preparation using 6-bromo-2-chloro-8-methylquinoline and sodium methoxide as the starting materials.
- 6-Bromo-2-chloroquinoline is a known compound.
-
- Trans-3-ethoxypropenoyl chloride (0.74 g) was added at 0° to a stirred solution of 4-bromo-2-methylaniline (0.93 g) in pyridine (10 cm3). After 0.5 hours water (40 cm3) was added, the solid material was filtered off, washed with water (30 cm3) and dried. The product was recrystallised from ethyl acetate to afford trans-N-(4-bromo-2-methylphenyl)-3-ethoxypropenamide, m.p. 163-164°, (1.3 g).
- Trans-N-(4-iodophenyl)-3-ethoxypropenamide, m.p. 181-182°, was prepared similarly to the previous Preparaton using trans-3-ethoxypropenoyl chloride and 4-iodoaniline as the starting materials.
-
- Trans-N-(4-bromo-2-methylphenyl)-3-ethoxypropenamide (2.0 g) was added portionwise with stirring to 98% sulphuric acid (15 cm3) at room temperature. After 16 hours the solution was poured onto ice (100 cm3) and the resulting precipitate was filtered off and dried (1.5 g). Recrystallisation from ethyl acetate-methanol afforded 6-bromo-8-methyl-2-(1H)-quinoline, m.p. 272-274°.
- 6-lodo-2-(lH)-quinolone, m.p. 260-263°, was prepared similarly to the previous Preparation using trans--N-(4-iodophenyl)-3-ethoxypropenamide and 98% sulphuric acid as the starting materials.
-
-
- A mixture of 6-bromo-8-methyl-2-(1H-quinoline (12.0 g) in phosphorus oxychloride (100 cm3) was heated under reflux for 2 hours. Volatile material was removed in vacuo, the residue dissolved in chloroform (200 cm3), and the resulting solution was poured onto ice (200 g). The mixture was basified with aqueous ammonia solution (S.G. 0.88) to pH 10 and the aqueous phase was further extracted with chloroform (2 x 100 cm3). The combined and dried (MgS04) extracts were concentrated in vacuo to give a solid (10.7 g) which was recrystallised from ethanol to afford 6-bromo-2-chloro-8-methyl-quinoline, m.p. 114-116°.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT86300524T ATE51224T1 (en) | 1985-01-30 | 1986-01-27 | QUINOLONE INOTROPIC AGENTS. |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858502267A GB8502267D0 (en) | 1985-01-30 | 1985-01-30 | Quinolone inotropic agents |
GB8502267 | 1985-01-30 | ||
CN85104392A CN85104392B (en) | 1985-01-30 | 1985-06-10 | Process for preparing quinolone inotropic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0190857A2 EP0190857A2 (en) | 1986-08-13 |
EP0190857A3 EP0190857A3 (en) | 1987-08-19 |
EP0190857B1 true EP0190857B1 (en) | 1990-03-21 |
Family
ID=25741743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86300524A Expired - Lifetime EP0190857B1 (en) | 1985-01-30 | 1986-01-27 | Quinolone inotropic agents |
Country Status (18)
Country | Link |
---|---|
US (1) | US4728654A (en) |
EP (1) | EP0190857B1 (en) |
JP (1) | JPS61176568A (en) |
KR (1) | KR880000132B1 (en) |
CN (1) | CN85104392B (en) |
AT (1) | ATE51224T1 (en) |
AU (1) | AU557667B2 (en) |
CA (1) | CA1255662A (en) |
DE (1) | DE3669714D1 (en) |
DK (1) | DK43286A (en) |
ES (2) | ES8706122A1 (en) |
FI (1) | FI860424A (en) |
GB (1) | GB8502267D0 (en) |
GR (1) | GR860249B (en) |
HU (1) | HU194831B (en) |
IE (1) | IE860258L (en) |
PL (1) | PL257669A1 (en) |
PT (1) | PT81921B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102532015A (en) * | 2012-01-18 | 2012-07-04 | 云南大学 | Solid-phase synthesis method of coumarin and analogue thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
US4797490A (en) * | 1984-12-06 | 1989-01-10 | Pfizer Inc. | Process for the preparation of 3-(2'-fluorophenyl)pyridine |
GB8709448D0 (en) * | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JP2686887B2 (en) * | 1992-08-11 | 1997-12-08 | キッセイ薬品工業株式会社 | Piperidino-3,4-dihydrocarbostyril derivative |
MY146795A (en) * | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3287459A (en) * | 1961-10-23 | 1966-11-22 | Chattanooga Medicine Co | Carbostyrils, coumarines and thiocoumarines |
US3668207A (en) * | 1970-01-22 | 1972-06-06 | Ciba Geigy Corp | 2-amino-4-aryl-quinolines |
BE884459Q (en) * | 1971-05-14 | 1981-01-26 | Boehringer Mannheim Gmbh | 4- (OMEGA- (COUMARINE-7-YL-OXY) -ALKYL) -PIPERAZINE DERIVATIVES AND PREPARATION METHOD |
DE2123923A1 (en) * | 1971-05-14 | 1972-11-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Square bracket on omega- (Flavon-7yl-oxy) -alkyl Square bracket on -pigerazine derivatives and process for their preparation |
JPS4976877A (en) * | 1972-11-28 | 1974-07-24 | ||
US4004012A (en) * | 1975-10-14 | 1977-01-18 | Sterling Drug Inc. | 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones |
DE2827566A1 (en) * | 1978-06-23 | 1980-01-10 | Boehringer Mannheim Gmbh | 1,2-DIHYDRO-CHINOLIN-2-ON DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
HU190412B (en) * | 1981-09-17 | 1986-09-29 | Warner-Lambert Co,Us | Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones |
US4503061A (en) * | 1983-07-22 | 1985-03-05 | Warner-Lambert Company | Substituted phenyl-pyridinones as cardiotonic agents |
IL69407A (en) * | 1982-08-23 | 1987-10-20 | Warner Lambert Co | 2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
US4550119A (en) * | 1983-05-23 | 1985-10-29 | Warner-Lambert Company | 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones |
US4710507A (en) * | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
CA1292234C (en) * | 1984-05-29 | 1991-11-19 | Simon Fraser Campbell | Heterocyclic-substituted quinolone inotropic agents |
-
1985
- 1985-01-30 GB GB858502267A patent/GB8502267D0/en active Pending
- 1985-06-10 CN CN85104392A patent/CN85104392B/en not_active Expired
-
1986
- 1986-01-27 EP EP86300524A patent/EP0190857B1/en not_active Expired - Lifetime
- 1986-01-27 AT AT86300524T patent/ATE51224T1/en not_active IP Right Cessation
- 1986-01-27 US US06/822,575 patent/US4728654A/en not_active Expired - Lifetime
- 1986-01-27 DE DE8686300524T patent/DE3669714D1/en not_active Expired - Fee Related
- 1986-01-28 PL PL25766986A patent/PL257669A1/en unknown
- 1986-01-28 GR GR860249A patent/GR860249B/en unknown
- 1986-01-28 CA CA000500469A patent/CA1255662A/en not_active Expired
- 1986-01-28 PT PT81921A patent/PT81921B/en unknown
- 1986-01-28 ES ES551343A patent/ES8706122A1/en not_active Expired
- 1986-01-29 IE IE860258A patent/IE860258L/en unknown
- 1986-01-29 AU AU52798/86A patent/AU557667B2/en not_active Ceased
- 1986-01-29 HU HU86408A patent/HU194831B/en not_active IP Right Cessation
- 1986-01-29 DK DK43286A patent/DK43286A/en not_active Application Discontinuation
- 1986-01-29 FI FI860424A patent/FI860424A/en not_active Application Discontinuation
- 1986-01-29 KR KR1019860000571A patent/KR880000132B1/en not_active IP Right Cessation
- 1986-01-30 JP JP61019171A patent/JPS61176568A/en active Pending
-
1987
- 1987-02-27 ES ES557430A patent/ES8801902A1/en not_active Expired
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102532015A (en) * | 2012-01-18 | 2012-07-04 | 云南大学 | Solid-phase synthesis method of coumarin and analogue thereof |
CN102532015B (en) * | 2012-01-18 | 2013-10-23 | 云南大学 | Solid-phase synthesis method of coumarin and analogue thereof |
Also Published As
Publication number | Publication date |
---|---|
AU557667B2 (en) | 1987-01-08 |
EP0190857A2 (en) | 1986-08-13 |
ES557430A0 (en) | 1988-03-01 |
FI860424A0 (en) | 1986-01-29 |
ATE51224T1 (en) | 1990-04-15 |
DK43286A (en) | 1986-07-31 |
HUT40421A (en) | 1986-12-28 |
JPS61176568A (en) | 1986-08-08 |
EP0190857A3 (en) | 1987-08-19 |
GR860249B (en) | 1986-05-29 |
AU5279886A (en) | 1986-08-07 |
DK43286D0 (en) | 1986-01-29 |
CA1255662A (en) | 1989-06-13 |
US4728654A (en) | 1988-03-01 |
GB8502267D0 (en) | 1985-02-27 |
IE860258L (en) | 1986-07-30 |
ES551343A0 (en) | 1987-06-01 |
PT81921A (en) | 1986-02-01 |
CN85104392A (en) | 1986-12-24 |
HU194831B (en) | 1988-03-28 |
ES8801902A1 (en) | 1988-03-01 |
KR880000132B1 (en) | 1988-03-12 |
PT81921B (en) | 1987-11-16 |
ES8706122A1 (en) | 1987-06-01 |
CN85104392B (en) | 1988-02-17 |
PL257669A1 (en) | 1987-05-18 |
KR860005790A (en) | 1986-08-13 |
FI860424A (en) | 1986-07-31 |
DE3669714D1 (en) | 1990-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5217976A (en) | 1,6-naphthyridone derivatives having angiotensin ii antagonist activity | |
US5254571A (en) | Chemical compounds | |
US4898872A (en) | Imidazo[4,5-b]pyridyl quinolone cardiac stimulants | |
KR870000911B1 (en) | Process for preparing quinolines | |
JP5060957B2 (en) | Heterocyclic compounds, production methods and uses thereof | |
JP3120873B2 (en) | Pyridine derivatives | |
EP0166533B1 (en) | Quinolone inotropic agents | |
EP2542084B1 (en) | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders | |
EP0288189A1 (en) | Improvements in or relating to leukotriene antagonists | |
EP0572425B1 (en) | Imidazopyridine paf/h 1 antagonists | |
JP2519880B2 (en) | Piperididenedihydro-dibenzo [a, b] cycloheptenes and pharmaceutical compositions containing the same | |
EP0190857B1 (en) | Quinolone inotropic agents | |
EP0347027B1 (en) | Phenylpyridone derivatives,processes for their preparation and pharmaceutical compositions containing them. | |
JP2012515188A (en) | Naphthyridin-2 (1H) -one compounds useful as antibacterial agents | |
KR20010085852A (en) | 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation | |
US4764519A (en) | 3-hydroxypyridines | |
EP1446381B1 (en) | Anthranilic acid amides and pharmaceutical use thereof | |
JPS6222768A (en) | Substituted tetrahydroisoquinoline derivative | |
US5198439A (en) | Angiotension II antagonizing pyridine derivatives | |
HUT53615A (en) | Process for producing thioformamide derivataives and pharmaceutical compositions comprising same | |
WO1996033997A1 (en) | Benzimidazole derivatives being dual histamine (h1) and platelet activating factor (paf) antagonists | |
WO1994011379A1 (en) | Heterocyclic compounds as angiotensin ii antagonists | |
JPH0832688B2 (en) | Phenoxyacetic acid derivative and pharmaceutical preparation containing the same | |
WO1993022285A1 (en) | Leukotriene antagonists | |
JP2794637B2 (en) | Imidazole derivative, method for producing the same, and anti-ulcer agent containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19860130 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19881018 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 51224 Country of ref document: AT Date of ref document: 19900415 Kind code of ref document: T |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 3669714 Country of ref document: DE Date of ref document: 19900426 |
|
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19910127 Ref country code: AT Effective date: 19910127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19910128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19910131 Ref country code: LI Effective date: 19910131 Ref country code: CH Effective date: 19910131 Ref country code: BE Effective date: 19910131 |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19910801 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19911001 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19940128 Year of fee payment: 9 |
|
EUG | Se: european patent has lapsed |
Ref document number: 86300524.5 Effective date: 19910910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19950929 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050127 |